Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96B02

UPID:
UBE2W_HUMAN

ALTERNATIVE NAMES:
E2 ubiquitin-conjugating enzyme W; N-terminal E2 ubiquitin-conjugating enzyme; N-terminus-conjugating E2; Ubiquitin carrier protein W; Ubiquitin-conjugating enzyme 16; Ubiquitin-protein ligase W

ALTERNATIVE UPACC:
Q96B02; B4DIV1; Q1XBE0; Q9H823; Q9HAG6; Q9NV07

BACKGROUND:
The Ubiquitin-conjugating enzyme E2 W, also known as UBE2W, is integral to the ubiquitin-proteasome system. It is distinguished by its ability to monoubiquitinate the N-termini of various proteins, a crucial step for their subsequent degradation or functional modification. This enzyme is also involved in the cellular response to DNA damage, specifically through the monoubiquitination of FANCD2, a key player in the repair of DNA interstrand crosslinks.

THERAPEUTIC SIGNIFICANCE:
The exploration of Ubiquitin-conjugating enzyme E2 W's functions offers promising avenues for drug discovery. Its central role in managing protein homeostasis and DNA repair processes makes it a compelling target for developing treatments for neurodegenerative disorders and improving cancer therapy outcomes by targeting DNA repair pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.